论文部分内容阅读
目的探讨小细胞肺癌(SCLC)患者血清胃泌素释放肽前体(Pro-GRP)的水平及意义。方法回顾分析60例SCLC患者和120例肺部良性病变患者的临床病理资料,分别作为SCLC组和良性组;同期体检健康者100例作为对照组。所有入组对象均进行血清Pro-GRP和神经元特异性烯醇化酶(NSE)检测,比较组间差异;以阳性标准Pro-GRP>77.8 pg/ml,NSE>16.3 ng/ml判断,比较不同诊断方法的灵敏度、特异度;比较SCLC患者不同分期及不同治疗效果患者Pro-GRP、NSE水平差异。结果 SCLC组血清Pro-GRP、NSE明显高于良性组和健康组(P<0.05)。Pro-GRP诊断SCLC的灵敏度为80.00%,高于NSE(P<0.05),ProGRP+NSE诊断SCLC的灵敏度为98.33%,高于Pro-GRP、NSE(P<0.05)。SCLC广泛期患者Pro-GRP、NSE高于SCLC局限期(P<0.05);SCLC治疗后缓解期、好转期的Pro-GRP、NSE低于治疗前,且缓解期低于好转期(P<0.05);治疗后进展期患者Pro-GRP、NSE高于治疗前(P<0.05)。结论 SCLC患者血清ProGRP水平呈高表达,其诊断SCLC的灵敏度高于NSE,并与肿瘤的分期及预后存在相关性。
Objective To investigate the level and significance of serum gastrin-releasing peptide (Pro-GRP) in patients with small cell lung cancer (SCLC). Methods The clinical and pathological data of 60 patients with SCLC and 120 patients with benign lung disease were retrospectively analyzed, which were taken as SCLC group and benign group respectively. 100 healthy subjects were taken as control group in the same period. Serum Pro-GRP and neuron-specific enolase (NSE) were detected in all subjects, and the differences between groups were compared. The positive rates of Pro-GRP> 77.8 pg / ml and NSE> 16.3 ng / ml were different Sensitivity and specificity of diagnostic methods; compare the levels of Pro-GRP and NSE in patients with different stages and different therapeutic effects of SCLC. Results Serum Pro-GRP and NSE in SCLC group were significantly higher than those in benign group and healthy group (P <0.05). The sensitivity of Pro-GRP in diagnosing SCLC was 80.00%, higher than NSE (P <0.05). The sensitivity of ProGRP + NSE in diagnosing SCLC was 98.33%, higher than Pro-GRP and NSE (P <0.05). The Pro-GRP and NSE in the extensive SCLC patients were higher than that in the SCLC patients (P <0.05). The Pro-GRP and NSE in the remission stage and the remission stage were lower than those before the SCLC treatment (P <0.05) ). Pro-GRP and NSE in patients with advanced stage after treatment were higher than those before treatment (P <0.05). Conclusion The serum level of ProGRP in SCLC patients is highly expressed. The sensitivity of SCLC in diagnosis of SCLC is higher than that of NSE, which is correlated with the stage and prognosis of the patients.